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The  sulfatide  activator  protein,  also  known as SAP- 
1, is derived from a gene that generates an mRNA 
coding  for  four homologous proteins. Its physiological 
function is to  stimulate  hydrolysis of sulfatide by ar- 
ylsulfatase A in vivo. A  genetic  defect  in  the  sulfatide 
activator results in a metabolic disorder similar to 
classical  metachromatic  leukodystrophy,  which is it- 
self  caused  by a genetic  defect in  arylsulfatase A. In a 
patient  with  sulfatide  activator deficiency, a nucleo- 
tide transversion G’” + C (counted from A of the 
initiation codon ATG) was found  in the mRNA  of the 
sulfatide  activator  precursor,  resulting  in  the  substi- 
tution of serine  for CysZ4l in  the  mature  sulfatide  ac- 
tivator. The remainder of the coding sequence was 
completely  normal  except for a polymorphism  C to T 
in position 1389, which  does  not  change  the  amino  acid 
sequence. The  patient  produces at  least  three  different 
forms of  mRNA for  the  precursor.  Two of them  include 
a stretch of an  additional 9 and 6 bases,  respectively, 
within  the  sulfatide  activator coding  region. In  normal 
individuals this stretch of additional bases has also 
been  observed. This could be  explained by the presence 
of a small  9-base  pair  exon  which  can  be  introduced, 
or not, by alternative  splicing as a stretch of 9 or 6 
bases into  the  mature mRNA. The  shortest  form of the 
mRNA yields an  active  sulfatide  activator (Fiirst, W., 
Schubert, J., Machleidt, W., Meier, H. E., and  Sand- 
hoff, K. (1990) Eur. J. Biochem. 192, 709-714). 
Physiological degradation of sulfatide (galactosylceramide 
sulfate) requires a lysosomal hydrolase, arylsulfatase A,’ and 
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an additional small lysosomal glycoprotein, the sulfatide ac- 
tivator protein (SAP-1) (1, 2). Genetic defects in either of 
these lysosomal proteins cause phenotypically similar disor- 
ders. Generically these disorders are classified as metachro- 
matic leukodystrophy, in which an abnormal accumulation of 
sulfatides occurs in most organs, most prominently in the 
nervous system. In addition to sulfatide degradation, the 
sulfatide activator  can  activate in  vitro degradation of GM? 
ganglioside by ,&galactosidase (3)  and globotriaosylceramide 
by a-galactosidase A (3,4).  The cDNA coding for the sulfatide 
activator,  first reported by Dewji et al. (5), has been  recognized 
more recently to code for four different proteins (6-10). The 
gene generates processed mRNA, which is translated  into  a 
large precursor polypeptide, which is in turn post-translation- 
ally processed to yield four small, homologous proteins. The 
sulfatide activator is the second among the four protein do- 
mains from the N  terminus of the nascent polypeptide. The 
third  protein (Al activator, SAP-2, Gaucher factor) is known 
to activate degradation of glucosylceramide by glucosylcer- 
amidase (11). Its physiological role is established because a 
Gaucher-like disorder occurs when it is genetically defective 
(12). Activation of the hydrolysis of sphingomyelin and glu- 
cosylceramide by the  other two processed proteins  has been 
reported in  vitro in the presence of detergents (13, 14). The 
physiological significance of these two proteins  has  not been 
established definitively. 
The mRNA of the precursor of the sulfatide activator from 
normal individuals exhibits polymorphism. Beside the  short- 
est mRNA  which is colinear with the amino acid sequence of 
the mature sulfatide activator  protein (15), a longer one with 
an additional stretch of 9 bases within the sulfatide activator 
coding region has been described (10). In  the present  paper 
we found that some mRNA contains only the 6 3”terminal 
bases of the 9-base stretch. Furthermore, Zhang et al. (16) 
found, in a patient with a genetic defect in the sulfatide 
activator, a 33-base insertion with the last 9 bases being 
identical to those found in normal individuals. The source of 
these  inserted sequences has yet not been clarified. In addition 
to  the 33-base insertion,  a  point  mutation within the sulfatide 
activator which abolishes the only glycosylation site has been 
identified in another patient with sulfatide activator defi- 
ciency (17, 18). 
We describe in this  report the source and mechanism for 
the polymorphism of the mRNA for the sulfatide activator 
The abbreviated  designations of glycolipids are according to  Sven- 
nerholm’s nomenclature for ganglio series  gangliosides (Svennerholm, 
L. (1963) J .  Neurochem. 10,613-623). 
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precursor and  a newly found point  mutation responsible for 
the clinical phenotype of sulfatide.activator deficiency. 
EXPERIMENTAL  PROCEDURES 
Patient 
The patient is a 7-year-old Arabic  boy, the  third of four children 
of parents who are first cousins. There is no family history of 
neurological illness. The patient was initially described as  an abnor- 
mal case of metachromatic leukodystrophy with normal arylsulfatase 
A  hut disturbed fibroblastic sulfatide t ~ r n o v e r . ~  These findings col- 
lectively indicated sulfatide activator deficiency as  the cause of the 
disease. The diagnosis was confirmed by the absence of cross-reactive 
materials against anti-sulfatide activator antiserum  in fibroblast ex- 
t r a c t ~ . ~  Cross-reactive material, however, was present for the AI 
protein (SAP-2, glucosylceramidase activator, Gaucher factor) (19). 
Commercial Materials 
Restriction endonucleases, T, ligase, polynucleotide kinase, DNA 
polymerase (Klenow), and the T7 polymerase sequencing kit were 
obtained from Pharmacia LKB Biotechnology Inc. Avian myeloblas- 
tosis reverse transcriptase was obtained from Promega Biotec (Mad- 
ison, WI),  and  Taq polymerase was from Perkin-Elmer Cetus Instru- 
ments. [T-~’P]ATP, [w3*P]dATP, and [35S]dATP were obtained from 
Amersham Corp. The oligonucleotide primers were synthesized in the 
nucleotide synthesis laboratory of the Program in Molecular Biology 
and Biotechnology, University of North Carolina, under the super- 
vision of Dr. Dana Fowlkes and in the Institut f i r  Genetik der 
Universitat Bonn under the supervision of Hella Lichtenberg-Frate. 
Cell Lines 
The cultured fibroblasts of the patient were first established in 
Tubingen, FRG, from a primary culture provided by Dr. Haas-Andela 
(Giessen, FRG). They and the normal control skin fibroblasts, ob- 
tained from a  patient with juvenile form of Sandhoff disease, were 
maintained in Eagle’s minimal essential medium supplemented with 
10% fetal calf serum, 0.48% glucose, and 1% penicillin/streptomycin. 
The cells  were harvested in  a solution of 150 mM NaCl with a rubber 
scraper. 
Methods 
Isolation of RNA-The guanidine isothiocyanate-cesium chloride 
method was used to isolate RNA from cultured fibroblasts (20). The 
poly(A)-positive RNA fraction was prepared by affinity chromatog- 
raphy on oligo(dT)-cellulose. Northern transfer of electrophoresed 
mRNA onto Nylon membrane was done according to Maniatis  et al. 
(20). 
Isolation of Genomic  DNA-Genomic DNA was isolated from cul- 
tured skin fibroblasts. After removing the culture medium and wash- 
ing the monolayer with phosphate- buffered saline the cells were 
harvested in a solution of  150 mM NaCl with a rubber scraper. After 
washing three times in phosphate-buffered saline the cells were 
resuspended in 0.3 ml of 150 mM NaCl solution containing 25 mM 
EDTA. The cell suspension was frozen at -70 “C  and thawed. 50  pl 
of proteinase K solution (20 mg/ml) and 10% sodium dodecyl sulfate 
solution were added per 100 pl of suspension and left at 37 “C 
overnight. Genomic DNA was extracted with phenol/chloroform, 
precipitated with ethanol in the presence of 0.5 volume of 7.5 M 
ammonium acetate, and washed  twice with 70% ethanol. Dried ge- 
nomic DNA  was  dissolved in water by warming to 37 “C for 1-2 h. 
Polymerase Chain Reaction-The poly(A)-positive RNA fraction 
was used as  the starting material for amplification of the entire coding 
sequence of the sulfatide activator precursor. The first (antisense) 
cDNA strand was synthesized with the Promega cDNA synthesis  kit 
using oligo(dT) as  the primes and avian myeloblastosis reverse tran- 
scriptase. The entire protein coding sequence including 33 bases of 
5”untranslated region and 77 bases of 3”untranslated region (nucle- 
otides -33 to 1661) was amplified in overlapping segments using a 
series of synthetic oligonucleotide primers (Fig. 1) with Taq polym- 
erase in a  thermal cycler (Biometra, Gottingen, FRG). The amplifi- 
cation conditions were: initial denaturation at  94 “C for 5 min, 30 
cycles of amplification with annealing for 3 min at 10 “C below the 
’’ Schlote, W., Harzer, K., Christomanou, H., Paton, B.  C., Kuster- 
mann-Kuhn, B., Schmid, B., Seeger, J., Beudt, U., Schuster, I., and 
Langenbeck, U. (1991) Eur. J. Pediatr., in press. 
Nutation 
H , - 
FIG. 1. Strategy for amplification of the mRNA of the pre- 
cursor of the sulfatide activator. The four white  regions represent 
the four protein domains (A, saposin A; B,  sulfatide activator; C, A1 
activator; D, component C). 0, the coding  region of the precursor of 
the sulfatide activator from ATG to TAG; 0, noncoding region. The 
precursor of the sulfatide activator cDNA covering the entire protein 
coding sequence was obtained in three overlapping segments (thin 
continuous lines) by polymerase chain reaction. It used three pairs of 
synthetic oligonucleotide primers (a  and  b, c and d, e and f) .  The 
cDNA  was amplified and sequenced from 33 base pairs before ATG 
and  to 77 base pairs  after the stop codon (position 1661 numbered 
from A of the initiation codon). kb, kilobases. a = 5’GGC GCA TTG 
CAG ACT  GCG G 5’sense primer, h = 5’GTC TTT GCA TAT GTC 
GCA  GGG 5’antisense primer, c = 5’TCC TTG GAC TGA AAG  AA 
5’sense primer, d = 5’TTG TTG  TTG TCA ATG AG 5’antisense 
primer, e = B’CGC CTG GGC CCT GGC  ATG  GCC 5’sense primer, 
f = 5’GTG CGT TCA TTC CCC  CAG  ACA  CAC 5’antisense primer. 
lower of the calculated dissociation temperature of the two primers, 
extension at 72 “C for 2 min, and the final extension at 72 “C for 10 
min. 
An intronic segment flanking the variable stretch of 9 bp4 was 
amplified from the patient’s genomic DNA with a pair of primers 
synthesized from the intron sequence which had been determined 
from genomic fragments obtained from a normal human genomic 
library in X EMBL-4.5 The sequence of the primers were 5’- 
GCTGGCCCAGAGCAGACATTCA  (5’ primer, sense strand)  and 5’- 
TGGAGAGTCTCCTAGCCAGAGG (3’ primer, antisense strand). 
The amplification procedure was as described above. 
Sequencing of Polymeruse Chain Reaction Products-The amplified 
DNA segments were subcloned into  the plasmid pUC18 using the 
SmaI site. The plasmids containing subclones of interest were iden- 
tified by hybridization with appropriate radiolabeled oligonucleotides. 
Sequencing was done by the dideoxy chain  termination method (21) 
on the double-stranded pUC18  DNA. The T7 polymerase sequencing 
kit from Pharmacia was used with appropriate sequencing primers 
and  dATPaS. 
RESULTS 
A preliminary Northern  blotting study indicated that fibro- 
blasts of the patient generated stable mRNA for the sulfatide 
activator precursor of normal size (data not shown). This 
finding allowed us to approach the gene abnormality in  the 
patient from an examination of mRNA/cDNA. 
Sequencing of the cDNA clones covering the entire protein 
coding region showed that there was a single nucleotide 
change at position 722 (counted from A of the initiation codon 
ATG) from the normal G to C (Fig. 2). This transversion was 
observed in all of the five batches of cDNA clones, each 
prepared by amplification of different batches of cellular 
RNA. The remainder of the protein coding sequence was 
entirely normal except for a polymorphism C to T in position 
1398, which does not change the amino acid sequence (not 
shown). The transversion results in a  substitution of serine 
for normal cysteine (Fig. 2). At the genomic  level this  muta- 
tion was observed after six different polymerase chain reac- 
*The abbreviations used are: bp, base pair(s); dATPaS, deoxy- 
Holtschmidt, H., Sandhoff, K., Furst, W., Kwon, H. Y., Schnabel, 
adenosine 5’-[a-35S]thiotriphosphate. 
D., and Suzuki, K. (1991) FEES Lett., in press. 
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FIG. 2. Mutation in  the  patient 
and  the  presence of three  alterna- 
tive mRNAs. The figures represent  the 
coding strand.  The  mutation  at nucleo- 
tide 722 (numbered from  A of the  initi- 
ation codon) from the  normal G to C in 
the  patient  alters  the codon 241 from the 
normal cysteine (TGC) (sequence I )  to 
serine  (TCC) (sequences 2-4). The aster- 
isks and arrows denote the location of 
the base  change. This figure also  depicts 
the  area  representing  the  9-base  and  the 
6-base exon. The left  sequence (sequence 
I )  shows the normal control with an 
additional 9 bases. The following se- 
quences (2-4)  show the patient cDNA 
with  an  additional 9 bases (sequence 2) ,  
an additional 6 bases (sequence 3 ) ,  and 
without  additional bases (sequence 4 ) .  
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tion amplifications in three of six sequenced clones. Three 
clones had  the  normal sequence in  this region. Fig. 3 shows 
the genomic structure  around  the respective exon  including 
the  mutation.  This exon is 57 bp long; the  mutated  base  is 
the  first G of the exon only 2 bases  after  the 5’ intron-exon 
junction. 
Three alternate forms of mRNA were observed (Fig. 2). 
Five of the 12  clones  sequenced had  the  largest  mRNA  con- 
taining  the  same  9-base  stretch originally  described by Nak- 
ano et al. (10) in  two normal individuals; 2 contained only  6 
bases also  described by Rafi et al. (17) on  the 3‘ terminus of 
the  9-base  stretch;  and 5 had  the  shortest  mRNA  that  did  not 
contain  the  9-base  stretch. 
To gain insight into the mechanism by which the  three 
alternate  forms of mRNA are  generated,  the g nomic segment 
flanking  this region was sequenced (Figs. 4 and 5). It  became 
clear that the stretch of the 9 bases found in the largest 
mRNA is  present  in  the gene in  this region. The  stretch  also 
included the  additional 24 bases  on  the 5’ side, comprising 
the 33-base insertion  found by Wenger  and colleagues  (16) in 
a patient with sulfatide activator deficiency. The  upstream 
portion of this region is rich in pyrimidines, and the 5‘ 
junctions of both  the 9-base and  the 6-base stretches  have 
sequences that conform to  the  consensus equences  for the 3‘ 
acceptor  site of an  intron-exon  junction, CAG CA and 
CAG GA. At the common 3’ terminus of the  9-base  and 6- 
base  stretches  there  is a  typical consensus sequence for  the 5‘ 
donor  site for an  exon-intron  junction, CAG GT.  Thus,  once 
either of the  upstream 3‘ acceptor  site  consensus  sequences 
is recognized as an intron-exon junction the downstream 
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consensus sequence is recognized as  the 5’ donor site. This 
mechanism  generates  in effect a 6-base or 9-base  exon. 
DISCUSSION 
The  stable mRNA of normal size and  with a single amino 
acid substitution  within  the  entire  protein coding sequence 
provides a priori evidence that  the nucleotide transversion, 
G7’2 -+ C, CysZ4’ Ser, could be responsible for the clinical 
and biochemical phenotype of the  sulfatide  activator  in  this 
patient.  Furthermore, all  6 cysteine residues including  the  one 
affected  by the  mutation  are  strictly conserved among  all of 
the four homologous proteins generated by this gene (10). 
Sodium dodecyl sulfate-gel  electrophoresis of sulfatide  acti- 
vator under nonreducing conditions results in an apparent 
molecular mass of 16,000 Da  and  under reducing conditions 
in  an  apparent molecular mass of 8,000 Da, suggesting that 
disulfide bond formation might be functionally critical in 
these  proteins?  The  failure  to form normal disulfide bonds 
and  the  resultant  disruption of the  normal  three-dimensional 
structure are likely to make the mutant sulfatide activator 
protein unstable, consistent with the lack of cross-reactive 
material  in  the  patient’s tissues. The possibility cannot be 
completely ruled  out, however, that  he  conformational 
changes  in  the  mutant  sulfatide  activator  protein  make  it  no 
longer  recognizable  by the  antibody. 
Because of the family history of consanguinity and the 
consistent  finding of the  transversion  in five successive in- 
dependent  clones we expected the  patient  to be homozygous 
R. Hunvitz  and K. Sandhoff,  unpublished observations. 
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FIG. 3. Mutation in  the  patient at the genomic level. The 
figure represents the coding strand of the normal control (left) and 
the mutation (right). The whole exon including the mutation and 
parts of the upstream and downstream introns are shown. Amplifi- 
cation and sequencing of the patient's DNA yielded the mutated 
sequence (three times) as well as the normal sequence (three times). 
Exon nucleotides are written in upper case letters, intron nucleotides 
in lower  case letters. The asterisks and  the arrows denote the location 
of the base change. 
for the mutation. Amplification and sequencing of the ge- 
nomic DNA around  the  mutation, however, yielded the  mu- 
tated sequence (three  times) as well as the  normal sequence 
(three  times) (Fig. 3). This  finding suggests that  the  patient 
is a  compound  heterozygote with  the identified mutation  in 
one allele and  another  as  yet  unidentified  mutation  in  the 
other allele, which might be of an  mRNA-negative  type.  The 
mutation found in  our  patient, G7** + C, CYS'~' + Ser,  is  the 
third known mutation responsible for  sulfatide  activator  de- 
ficiency. The other :two are the 33-base insertion at the 
location of the  normal  9-base  exon  site (16) and a mutation 
that abolishes the single glycosylation site of the sulfatide 
activator  protein (17, 18). 
The finding of three  alternative  forms of the  mRNA for the 
sulfatide activator  precursor which would generate  three dif- 
ferent forms of the sulfatide activator protein raises two 
important questions: what is the  mechanism  that  generates 
the  three forms and  what  is  the  potential  functional signifi- 
cance of the  three forms? The  observations described in  this 
report clearly answer  the  first question. An unusual  feature 
in  an  intronic sequence causes  apparently  random recognition 
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t 
9 
t intron 
9 
3'  
intron 5 '  
donor s i t e  
C 
FIG. 4. The  sequence of the genomic structure of a normal 
individual  around  the 9-bp exon. The figure represents the coding 
strand. Consensus sequences for the 3' acceptor sites (ag and AG) 
and  the 5' donor site (gt) exist flanking the exon. Exon nucleotides 
are written in upper case letters, intron nucleotides in lower case 
letters. The two alternative splicing possibilities are indicated. 
exon intron 
. . .AT Sta- tccgatttcctgtttttttgttcaaca AQ AT \J/ 7 
FIG. 5. The intronic sequence around the observed 9-bp 
exon. Consensus sequences for the 3' acceptor (ag and AG) and 5' 
donor sites ( g t )  exist flanking the exon sequence. Exon nucleotides 
are written in upper case letters, intron nucleotides in lower cme 
letters. The insertion of the  patient described by Zhang et al. (16) is 
represented as bold lower  case letters. Lower solid arrow, no addition1 
bp; upper solid arrows, 6 additional bp; open arrow, 9 additional bp. 
of the  stretches of either 9 or 6 bases  as if they were very 
short exons. When recognized as exons, these  stretches of 6 
or 9 bases  are spliced into  the  mature  mRNA whereas in  other 
cases they are spliced out along with the flanking intron 
sequences. Furthermore,  since  the 33-base insertion  found by 
Zhang et al. (16) in their patient with sulfatide activator 
deficiency is  also located at  the  same  site  as  the  short exons, 
one  can  predict a point  mutation immediately upstream of 
the 33 bases which generates a consensus sequence  for  a new 
3' acceptor site. We  learned recently that  Zhang et al. (22) 
has  also reached the  same conclusion  regarding the mecha- 
nism that  generates  the  three  alternative  mRNAs  and  that 
his patient has the predicted mutation in the intronic se- 
quence immediately preceding the sequence of the 33-base 
insertion. 
In  contrast,  there  is  no  experimental  basis  for  answering 
the  question  regarding  the  functionality of the  three  alterna- 
tive  mRNAs of the  precursor of the  sulfatide  activator protein. 
The shortest mRNA seems to be functional. I t  is colinear 
with  the  amino acid  sequence of the  mature  sulfatide  activator 
protein (15). Since the additional stretches in the larger 
mRNAs  are  in-frame,  they will be translated  into  three  dif- 
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ferent  proteins differring from each other only in two or three 
inserted amino acids. The mRNAs with additional  stretches 
do occur with sufficient frequency so that they too can be of 
potential functional significance. The sulfatide activator  has 
been reported to stimulate in vitro degradation of other gly- 
cosphingolipids like Gut ganglioside and globotriaosylceram- 
ide.  Although it is tempting to speculate that  the  three alter- 
native forms all have properties of activator proteins with 
different substrate specificities it is equally possible that only 
one of these three  proteins functions as  an activator  protein 
and  that  the other two have either no, or different, physiolog- 
ical activities. Further  experiments  are required to clarify this 
question. 
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